However, the IRA’s impact on the pharmaceutical industry in the United States remains uncertain, in part because multiple large pharmaceutical companies and other stakeholders (e.g., the U.S. Chamber of Commerce) have initiated federal lawsuits against CMS arguing the program is unconstitutional for a variety of reasons, among other complaints. Those lawsuits are currently ongoing.
All entries for: Endocrinology
March 13, 2026
Nektar Therapeutics
Neutral Outlook
San Francisco, CA
51-200 employees
Although the effects of the IRA on our business and the healthcare industry in general are not yet known, we are taking into consideration the potential impact of the IRA on our development and commercialization activities.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Neurological Diseases, Oncology
Drug Type: Biologic
March 9, 2026
Macrogenics Inc
Neutral Outlook
Rockville, MD
201-500 employees
For example, on August 16, 2022, the Inflation Reduction Act of 2022 (IRA) was signed into law, which among other things, (i) extends enhanced subsidies for individuals purchasing health insurance coverage in ACA marketplaces through plan year 2025, (ii) authorizes HHS to negotiate the price of certain high-expenditure, single-source drugs covered under Medicare that have been on the market for at least 7 years, and (iii) imposes rebates with respect to certain drugs and biologics covered under Medicare Part B or Medicare Part D to penalize price increases that outpace inflation.
Disease Area: Endocrinology, Hematology, Oncology
Drug Type: Biologic
March 9, 2026
Septerna Inc
Neutral Outlook
South San Francisco, CA
51-200 employees
It is unclear how the IRA will be implemented but is likely to have a significant impact on the pharmaceutical industry.
Disease Area: Dermatology, Endocrinology, Immune Diseases, Metabolic Diseases
Drug Type: Small Molecule
March 5, 2026
Lexicon Pharmaceuticals
Negative Outlook
The Woodlands, TX
51-200 employees
Many experts and analysts, both within the industry and outside, have predicted that the law will harm innovation in the pharmaceutical industry and result in fewer new treatments being developed and approved over time.
Disease Area: Cardiology, Endocrinology, Metabolic Diseases, Neurological Diseases
Drug Type: Small Molecule
March 3, 2026
Lineage Cell Therapeutics
Neutral Outlook
Carlsbad, CA
51-200 employees
In August 2022, the Inflation Reduction Act of 2022 was signed into law by President Biden. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of paying a monthly premium for outpatient prescription drug coverage. Among other things, the Inflation Reduction Act of 2022 requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The Inflation Reduction Act of 2022 permits the Secretary of the HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.
Disease Area: Endocrinology, Neurological Diseases, Rare Diseases
Drug Type: Biologic
March 3, 2026
Sana Biotechnology/WA
Neutral Outlook
Seattle, WA
201-500 employees
Most significantly, on August 16, 2022, President Biden signed the Inflation Reduction Act of 2022 (IRA) into law. This statute marks the most significant action by Congress with respect to the pharmaceutical industry since adoption of the ACA in 2010. Among other things, the IRA requires, beginning in 2026, that manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates, first due in 2023, under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation; and, beginning in 2025, replaces the Part D coverage gap discount program with a new discounting program.
Disease Area: Endocrinology, Hematology, Immune Diseases, Oncology
Drug Type: Biologic